Abstract
We appreciate our Italian colleagues’ interest in our editorial denoting the rheumatologist’s role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the coronavirus disease 2019 (COVID-19) pandemic1. It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) treated with background biological disease-modifying antirheumatic drug (bDMARD) therapies in Milan, Italy, surveyed over a 7-week period from February 25 through April 14, 2020 (during which time COVID-19 was hyperendemic there), had either confirmed or suspected COVID-192.